Clinical evidence suggests that debulking surgery in patients with metastatic disease could enhance response to immune checkpoint therapy. Here the authors report the results of a clinical trial of immune checkpoint inhibitors plus debulking surgery in patients with metastatic renal cell carcinoma.
- Sangeeta Goswami
- Jianjun Gao
- Padmanee Sharma
